0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

CLINICAL SYNTHESIS   |    
Self-Assessment Activity: Understanding the Evidence for Off-Label Use of Atypical Antipsychotic Medications
FOCUS 2014;12:172-177. doi:10.1176/appi.focus.12.2.172
View Author and Article Information

CME Information and Program Planner and Consultant Disclosures

Earn up to 5 CME Self-Assessment credits (MOC Part 2)through completion of this special activity online at apaeducation.org

Supported by a grant from the Agency for Healthcare Research and Quality (R18 HS021944)

Deborah J. Hales, M.D., Director, American Psychiatric Association Division of Education, Arlington, VA

Eve K. Mościcki, Sc.D., M.P.H., Director, Practice Research Network American Psychiatric Foundation, Arlington, VA

Robert Boland, M.D., Professor of Psychiatry and Human Behavior, Brown Alpert Medical School

David Fogelson, M.D., Clinical Professor of Psychiatry, UCLA Department of Psychiatry and Bio-behavioral Sciences

Research Support: Genentech.

Ian A. Cook, M.D., Professor of Psychiatry, David Geffen School of Medicine and Semel Institute for Neuroscience and Human Behavior at UCLA

Disclosures past 5 years: Grant Support: Aspect Medical Systems/Covidien, Cyberonics, Eli Lilly, MedAvante, Merck, Neuronetics, Novartis, Pfizer, Seaside Therapeutics, Sepracor, Shire. Adviser/Consultant: Allergan, Ascent Media, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest, Janssen, Neuronetics, NeuroSigma, NIH (ITVA), Pfizer, Scale Venture Partners, VA (DSMB) ; Speaker: Bristol-Myers Squibb, CME LLC, Eli Lilly, Medical Education Speakers Network, Neuronetics, NeuroSigma, Pfizer, Wyeth. Biomedical Device Patents assigned to the University of California. Stock Options: NeuroSigma.

Joel Yager, M.D. Professor of Psychiatry, University of Colorado School of Medicine.

Drs. Hales, Moscicki, Boland and Yager report no competing interests.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this enduring material for a maximum of five AMA PRA Category 1 Credits. Physicians should claim credit commensurate with the extent of their participation in the activity.

The American Board of Psychiatry and Neurology has approved this program as part of a comprehensive self assessment program, which is mandated by the ABMS as a necessary component of Maintenance of Certification.

The American Board of Psychiatry and Neurology has reviewed the American Psychiatric Association Clinical eFOCUS Program in psychiatry - of which this is a part - and has approved this program as part of a comprehensive self-assessment program, which is mandated by the ABMS as a necessary component of Maintenance of Certification.

Extract

In 2011, the Agency for Healthcare Quality and Research (AHRQ) published a comprehensive report (“Off-Label Use of Atypical Antipsychotics: An Update,” Comparative Effectiveness Review No. 43 [1]) summarizing the evidence for off-label use of antipsychotics for treatment of mental disorders (available at www.effectivehealthcare.ahrq.gov/reports/final.cfm). As described in the report, prescribing of atypical antipsychotics has moved beyond approved indications; however, the effectiveness, benefits, and adverse effects in off-label uses are not well understood. Through a grant from AHRQ, the American Psychiatric Association (APA) developed a FREE multipart CME program to disseminate the conclusions of the AHRQ report and to update clinicians about new developments regarding the evidence.

Figures in this Article

First Page Preview

View Large
First page PDF preview
Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Anchor for Jump
Table 1.Strength of Evidence Classificationsa
Table Footer Note

a From “Off-Label Use of Atypical Antipsychotics: An Update,” Comparative Effectiveness Review No. 43. September 2011, Agency for Healthcare Research and Quality, p 12.

+

References

Maglione  M;  Ruelaz  Maher A;  Hu  J;  Wang  Z;  Shanman  R;  Shekelle  PG;  Roth  B;  Hilton  L;  Suttorp  MJ;  Ewing  BA;  Motala  A;  Perry  T.  Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43. (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA290-2007-10062-1.) Rockville, MD: Agency for Healthcare Research and Quality. September 2011. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.
 
AHRQ Comparative Effectiveness Review Number 43. Off-Label Use of Atypical Antipsychotics: An Update. September 2011. Executive Summary
 
Off-Label Use of Atypical Antipsychotics: An Update. Summary Guide for Clinicians. John M. Eisenberg Center for Clinical Decisions and Communications Science. Comparative Effectiveness Review Summary Guides for Clinicians [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Aug 01. Available at: http://www.ncbi.nlm.nih.gov/books/NBK142851/
 
AHRQ Comparative Effectiveness Review Number 43. Off-Label Use of Atypical Antipsychotics: An Update. September 2011. Table A. AHRQ Report: Summary of strength of evidence of efficacy, by drug and condition p ES4. Table B: Summary Update: Efficacy of Atypical Antipsychotics for Off label use), ES 8. Table C. Summary update: safety of atypical antipsychotics for off-label use ES-11-13
 
Papakostas  GI;  Vitolo  OV;  Ishak  WW;  Rapaport  MH;  Zajecka  JM;  Kinrys  G;  Mischoulon  D;  Lipkin  SH;  Hails  KA;  Abrams  J;  Ward  SG;  Meisner  A;  Schoenfeld  DA;  Shelton  RC;  Winokur  A;  Okasha  MS;  Bari  MA;  Fava  M:  A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.  J Clin Psychiatry 2012; 73:1541–1547
[CrossRef] | [PubMed]
 
Maneeton  N;  Maneeton  B;  Srisurapanont  M;  Martin  SD:  Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials.  BMC Psychiatry 2012; 12:160
[CrossRef] | [PubMed]
 
Nelson  JC;  Papakostas  GI:  Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.  Am J Psychiatry 2009; 166:980–991
[CrossRef] | [PubMed]
 
Papakostas  GI;  Shelton  RC;  Smith  J;  Fava  M:  Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis.  J Clin Psychiatry 2007; 68:826–831
[CrossRef] | [PubMed]
 
Kohen  I;  Voelker  S;  Manu  P:  Antipsychotic-induced hyponatremia: case report and literature review.  Am J Ther 2008; 15:492–494
[CrossRef] | [PubMed]
 
Garvey  M;  Hollon  SD;  DeRubeis  RJ;  Evans  MD;  Tuason  VB:  Does 24-h urinary MHPG predict treatment response to antidepressants? I. A review.  J Affect Disord 1990; 20:173–179
[CrossRef] | [PubMed]
 
Friedman  MJ:  PTSD: Pharmacotherapeutic Approaches.  Focus 2013; 11:315–320
[CrossRef]
 
Krystal  JH;  Rosenheck  RA;  Cramer  JA;  Vessicchio  JC;  Jones  KM;  Vertrees  JE;  Horney  RA;  Huang  GD;  Stock  C; Veterans Affairs Cooperative Study No. 504 Group:  Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.  JAMA 2011; 306:493–502
[CrossRef] | [PubMed]
 
Department of Veterans Affairs, Department of Defense: Clinical Practice Guideline For Management Of Post-Traumatic Stress, version 2.0. Oct 2010. Available at: http://www.healthquality.va.gov/post_traumatic_stress_disorder_ptsd.asp
 
Hoge  CW:  Interventions for war-related posttraumatic stress disorder: meeting veterans where they are.  JAMA 2011; 306:549–551
[CrossRef] | [PubMed]
 
Herrmann  N;  Lanctôt  KL;  Hogan  DB:  Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.  Alzheimers Res Ther 2013; 5(Suppl 1):S5
[CrossRef] | [PubMed]
 
Lopez  OL;  Becker  JT;  Chang  Y-F;  Sweet  RA;  Aizenstein  H;  Snitz  B;  Saxton  J;  McDade  E;  Kamboh  MI;  DeKosky  ST;  Reynolds  CF  3rd;  Klunk  WE:  The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer’s disease.  Am J Psychiatry 2013; 170:1051–1058
[CrossRef] | [PubMed]
 
Keenmon  C;  Sultzer  D:  The role of antipsychotic drugs in the treatment of neuropsychiatric symptoms of dementia.  Focus 2013; 11:32–38
[CrossRef]
 
Rummel-Kluge  C;  Komossa  K;  Schwarz  S;  Hunger  H;  Schmid  F;  Lobos  CA;  Kissling  W;  Davis  JM;  Leucht  S:  Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.  Schizophr Res 2010; 123:225–233
[CrossRef] | [PubMed]
 
Bereza  BG;  Machado  M;  Ravindran  AV;  Einarson  TR:  Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder.  Can J Psychiatry 2012; 57:470–478
[PubMed]
 
Davidson  JR:  First-line pharmacotherapy approaches for generalized anxiety disorder.  J Clin Psychiatry 2009; 70(Suppl 2):25–31
[CrossRef] | [PubMed]
 
Woods  SW;  Morgenstern  H;  Saksa  JR;  Walsh  BC;  Sullivan  MC;  Money  R;  Hawkins  KA;  Gueorguieva  RV;  Glazer  WM:  Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.  J Clin Psychiatry 2010; 71:463–474
[CrossRef] | [PubMed]
 
Yager J, Devlin JM, Halmi KA, Herzog DB, Mitchell III JE, Powers P, Zerbe KJ. Guideline Watch (Aug 2012): Practice Guideline for the Treatment of Patients with Eating Disorders, 3rd Edition. American Psychiatric Association, Arlington VA (link to on POL or better to just provide the pdf and link)
 
Kishi  T;  Kafantaris  V;  Sunday  S;  Sheridan  EM;  Correll  CU:  Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis.  J Clin Psychiatry 2012; 73:e757–e766. Available at doi: 10.4088/JCP.12r07691
[CrossRef] | [PubMed]
 
Kafantaris  V;  Leigh  E;  Hertz  S;  Berest  A;  Schebendach  J;  Sterling  WM;  Saito  E;  Sunday  S;  Higdon  C;  Golden  NH;  Malhotra  AK:  A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa.  J Child Adolesc Psychopharmacol 2011; 21:207–212
[CrossRef] | [PubMed]
 
Kishi  T;  Sevy  S;  Chekuri  R;  Correll  CU:  Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials.  J Clin Psychiatry 2013; 74:e642–e654. Available at doi: 10.4088/JCP.12r08178
[CrossRef] | [PubMed]
 
Kishi  T;  Matsuda  Y;  Iwata  N;  Correll  CU:  Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.  J Clin Psychiatry 2013; 74:e1169–e1180
[CrossRef] | [PubMed]
 
Coffin  PO;  Santos  GM;  Das  M;  Santos  DM;  Huffaker  S;  Matheson  T;  Gasper  J;  Vittinghoff  E;  Colfax  GN:  Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.  Addiction 2013; 108:751–761
[CrossRef] | [PubMed]
 
Schutte-Rodin  S;  Broch  L;  Buysse  D;  Dorsey  C;  Sateia  M:  Clinical guideline for the evaluation and management of chronic insomnia in adults.  J Clin Sleep Med 2008; 4:487–504 Available at : http://www.aasmnet.org/Resources/clinicalguidelines/040515.pdf
[PubMed]
 
Shah  C;  Sharma  TR;  Kablinger  A:  Controversies in the use of second generation antipsychotics as sleep agent.  Pharmacol Res 2014; 79:1–8
[CrossRef] | [PubMed]
 
Maayan  L;  Correll  CU:  Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.  J Child Adolesc Psychopharmacol 2011; 21:517–535. Available at doi: 10.1089/cap.2011.0015
[CrossRef] | [PubMed]
 
Leichsenring F, Leibing E, Kruse J, New AS, Leweke F. Borderline personality disorder. Lancet. 2011; 377:74–84. Reprinted in FOCUS: March 2013; 11;249-260
 
Gunderson  JG;  Weinberg  I;  Choi-Kain  L:  Borderline personality disorder.  FOCUS 2013; 11:129–145
[CrossRef]
 
Ripoll  LH:  Psychopharmacologic treatment of borderline personality disorder.  Dialogues Clin Neurosci 2013; 15:213–224
[PubMed]
 
Birnbaum  ML;  Saito  E;  Gerhard  T;  Winterstein  A;  Olfson  M;  Kane  JM;  Correll  CU:  Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications.  Curr Psychiatry Rep 2013; 15:382
[CrossRef] | [PubMed]
 
Muscatello  MR;  Bruno  A;  Pandolfo  G;  Micò  U;  Scimeca  G;  Romeo  VM;  Santoro  V;  Settineri  S;  Spina  E;  Zoccali  RA:  Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.  J Clin Psychopharmacol 2011; 31:174–179
[CrossRef] | [PubMed]
 
Simpson  HB;  Foa  EB;  Liebowitz  MR;  Huppert  JD;  Cahill  S;  Maher  MJ;  McLean  CP;  Bender  J  Jr;  Marcus  SM;  Williams  MT;  Weaver  J;  Vermes  D;  Van Meter  PE;  Rodriguez  CI;  Powers  M;  Pinto  A;  Imms  P;  Hahn  CG;  Campeas  R:  Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.  JAMA Psychiatry 2013; 70:1190–1199
[CrossRef] | [PubMed]
 
Dold  M;  Aigner  M;  Lanzenberger  R;  Kasper  S:  Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.  Int J Neuropsychopharmacol 2013; 16:557–574
[CrossRef] | [PubMed]
 
Weiden  PJ:  EPS profiles: the atypical antipsychotics are not all the same.  J Psychiatr Pract 2007; 13:13–24
[CrossRef] | [PubMed]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 23.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 23.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>